Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis
Jinlan Piao, Hyun Ji Lim, Maria Lee
Obstet Gynecol Sci. 2020;63(3):346-356.   Published online 2020 Mar 24     DOI: https://doi.org/10.5468/ogs.2020.63.3.346
Citations to this article as recorded by Crossref logo
Preliminary outcomes of five-year survival for ovarian malignancies in profiled Serbian Oncology Centre
Bojana Gutic, Tatjana Bozanovic, Aljosa Mandic, Stefan Dugalic, Jovana Todorovic, Miroslava Gojnic Dugalic, Demet Sengul, Dzenana A. Detanac, Ilker Sengul, Dzemail Detanac, Tugrul Kesicioglu, José Maria Soares Junior
Clinics.2023; 78: 100204.     CrossRef
Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer
Daniele Fanale, Chiara Brando, Lidia Rita Corsini, Sofia Cutaia, Mariano Catello Di Donna, Ugo Randazzo, Clarissa Filorizzo, Chiara Lisanti, Luigi Magrin, Vittorio Gurrera, Raffaella Romano, Alessandra Dimino, Tancredi Didier Bazan Russo, Daniel Olive, Sa
BMC Cancer.2023;[Epub]     CrossRef
Prevalence and prognostic role of PD-L1 in patients with gynecological cancers: A systematic review and meta-analysis
Hanlin Fu, Zhihui Fu, Meng Mao, Lulu Si, Jing Bai, Qian Wang, Ruixia Guo
Critical Reviews in Oncology/Hematology.2023; 189: 104084.     CrossRef
The correlation of PD-L1 expression in cytological and histological material of serous high-grade ovarian cancer
Ljubiša Jovanović, Anđa Ćirković, Ljubinka Nikolić, Milena Jović, Darko Mikić, Svetlana Milenković, Radmila Janković
Srpski medicinski casopis Lekarske komore.2023; 4(3): 246.     CrossRef
Prognostic Significance of Programmed Cell Death Ligand 1 Expression in High-Grade Serous Ovarian Carcinoma: A Systematic Review and Meta-Analysis
Jeongwan Kang, Kang Min Han, Hera Jung, Hyunchul Kim
Diagnostics.2023; 13(20): 3258.     CrossRef
PD-L1 Expression in High-Grade Serous and Clear Cell Ovarian Cancer
Ljubiša Jovanović, Andja Ćirković, Milena Jović, Radmila Janković
Indian Journal of Gynecologic Oncology.2022;[Epub]     CrossRef
PD-L1 expression with QR1 and E1L3N antibodies according to histological ovarian cancer subtype: A series of 232 cases
Caroline Eymerit-Morin, Anna Ilenko, Thomas Gaillard, Justine Varinot, Eva Compérat, Sofiane Bendifallah, Emile Darai
European Journal of Histochemistry.2021;[Epub]     CrossRef
Intersection of DNA Repair Pathways and the Immune Landscape Identifies PD-L2 as a Prognostic Marker in Epithelial Ovarian Cancer
Samantha Batman, Koji Matsuo, Paulette Mhawech-Fauceglia, Elizabeth Munro, Mercedes Weisenberger, Allison Allen, Sonali Joshi, Hiroko Machida, Shinya Matsuzaki, Tatjana Bozanovic, Tanja Pejovic
Cancers.2021; 13(8): 1972.     CrossRef
The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
Margherita Turinetto, Giulia Scotto, Valentina Tuninetti, Gaia Giannone, Giorgio Valabrega
Frontiers in Oncology.2021;[Epub]     CrossRef
The role of immunotherapy in the management of metastatic/recurrent female reproductive system neoplasms
A. A. Rumyantsev, A. Yu. Anokhin
Meditsinskiy sovet = Medical Council.2021; (9): 76.     CrossRef
With Our Powers Combined
Lawrence Kasherman, Katherine Karakasis, Amit M. Oza
The Cancer Journal.2021; 27(6): 511.     CrossRef